Hodges Capital Management Inc.
Position in HALO — Halozyme Therapeutics, Inc.
CIK 1337263
DALLAS, TX
Position in HALO
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$10,337,197
+$1,631,795 QoQ
Shares Held
132,071
-1.9% QoQ
Ownership
0.116%
of shares outstanding
% of Portfolio
0.69%
of 13F equity value
Holder Rank
#116
of 664 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 78%
Shared 0%
None 22%
Common Shares in HALO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Hodges Capital Management Inc. holds $17,747,610 across 2 Biotechnology names. HALO ranks #1 (58.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
This page
|
132,071 | $10,337,197 | |
| 2 | LGND |
Ligand Pharmaceuticals Inc
|
23,444 | $7,410,413 |
All Filings in HALO
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10,337,197 | 132,071 | Shares | Sole | 2026-08-03 | |
| 2026-03-31 | $8,705,402 | 134,696 | Shares | Sole | 2026-04-28 | |
| 2025-12-31 | $7,628,724 | 113,354 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $8,815,908 | 120,206 | Shares | Sole | 2025-11-07 | |
| 2025-06-30 | $7,915,155 | 152,156 | Shares | Sole | 2025-08-07 | |
| 2025-03-31 | $12,351,382 | 193,565 | Shares | Sole | 2025-06-02 | |
| 2024-12-31 | $15,918,530 | 332,954 | Shares | Sole | 2025-01-24 | |
| 2024-09-30 | $18,347,938 | 320,544 | Shares | Sole | 2024-11-15 | |
| 2024-06-30 | $17,742,500 | 338,856 | Shares | Sole | 2024-08-02 | |
| 2024-03-31 | $12,897,390 | 317,045 | Shares | Sole | 2024-04-16 | |
| 2023-12-31 | $7,261,346 | 196,465 | Shares | Sole | 2024-02-13 | |
| No filing history on record for this holder in this stock. | ||||||